★NUTX
Nutex Health Inc. · Medical Care Facilities
1Y+29%B+
Rev+82.4%A
ROE27.8%A-
FCF$269mC
1Y Target$235.50Analyst consensus · 4 analysts
5Y Target$344.80Compound horizon
10Y Target$511.48Long-dated conviction
1Y+29%B+Up +29% over 12 months — strong uptrend
Rev+82.4%ARevenue +82.4% — hypergrowth, top decile
ROE27.8%A-ROE 27.8% — Buffett's preferred bar (>20%)
FCF$269mCFCF $269m — modest; watch for margin expansion
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 87
Quality0.71
Growth0.98
Value0.95
Entry · Margin of safety
52-week rangeMid-range22% off the 12-month high vs DCF fair value272% belowest. fair value ~$526
Quality signals · context only
Gross profitability90% · Agross profit ÷ total assets (Novy-Marx)
ROIC54.3% · Areturn on invested capital — not score-weighted
Why now
Medical Care Facilities · market cap $1.0b. Down 22% from 52-week high of $193.07 — deep drawdown territory. Revenue growing +82% — in hypergrowth territory. 4 sell-side analysts publish a mean 1-yr target of $235.50 (implying +57% upside).
Moat
ROE 28% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Beta 2.06 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon
1-3 yr $235.50 (4-analyst consensus) — fundamentals + valuation re-rating. 5 yr $344.80 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $511.48 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.
Position sizing · NUTX
Position size
$1,952
3.9% of portfolio
Stop price
$112.63
25% below $150.17
$ at risk if stopped
$488.05
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Nutex Health Inc. (NUTX): score, valuation & FAQ
Nutex Health Inc. (NUTX) is a Medical Care Facilities company that scores 87 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A), ROE (A-) and 1Y (B+). On valuation, NUTX implies roughly +272% upside versus our discounted-cash-flow fair value.
Is NUTX a good stock to buy?
Bull Rankings scores NUTX 87 out of 100 on its quality-growth model, which is a strong reading. That is driven by Rev (A), ROE (A-) and 1Y (B+). A score is a quantitative screen of Nutex Health Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does NUTX score 87 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). NUTX earns its highest marks on Rev (A), ROE (A-) and 1Y (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is NUTX overvalued or undervalued?
Based on $150.17, NUTX implies roughly +272% upside versus our discounted-cash-flow fair value. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in NUTX?
Beta 2.06 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.
Analyze another ticker →